What should be the pps at this point? I have said it in

New Post Public Reply Private Reply Replies (0) Message Board
xyz1002
What should be the pps at this point?

I have said it in the past that the pps could be as high as $0.50 and I could be totally wrong as it is a public company and more so in the great OTC land for now. So keep that aside. Let us try to put a valuation to it.

This is a 7 year old “Digital Media Tech Startup”. So let us keep that in mind.

How Much a VC would Value it.
If you showed this to 100 VC’s and ask them to put a valuation at this stage, you will get 100 different valuations and some maybe an order of magnitude difference. So there is no right and wrong – it boils down to who is willing to write a check - or as in this case, it will come down to supply and demand as it is a publicly traded stock. Startups are valued based on perception, timing and most important of all track record of the founder. Sean Parker got record valuation for Airtime even before a line of code was ever written because he was Sean Parker and the site was launched after more than a year of publicity stunts and TV appearance and no one used it after 7 days.

As such Revenue, Profit or PE are irrelevant when it comes to Startup valuation

Market size, Traction, growth potential and the founders are key. MagicLeap is valued at $4.5 billion with more than $1.3 billion investment with no product to show at all.

What Are Other Companies Valued it?

Snapchat is valued at $25 billion with projected $360M revenue for 2016. That is 69.4X Revenue multiple. That is gross revenue, NOT profit. That is one of the most successful businesses in digital media. I can site another 20 companies but you get the drift. Do as many as you want to your hearts, content. So a safe bet would be between 15X to 50X revenue. That is very wide and feel free to go with the lower numbers or whatever makes you comfortable.

So if the 2017 projected revenue say is $50M, the valuation at 15X is $750M. Divide that by 1.82 billion OS and you have a pps of around $0.40
If the revenue projection is $10M then the pps is still $0.08

Let us shift to a different reasoning.

Why Is the Company doing this


If you are one of the fellows who believes that this is an OTC scam and they will dump shares after the RS, STOP right here and please move to another OTC stock that is not diluting (pun intended).

They will not dump shares after RS. Period! It is suicidal for them. Makes zero sense for anyone with a brain.

Vert and possibly other investors must recoup tens or hundreds of millions of $$ from this. Plus you have potentially 100+ employees with ESO who have been working for years who will have to make millions. Otherwise, they won’t be still working there. Remember, when all said and done, ESO is generally between 15-25% of the entire OS.

So Vert and management must be thinking to take it to that valuation level for all parties to make money. So what valuation would that be? I don’t know but I am thinking at least north of $500 million to start with. Can they do it? Sure they can. After the RS, there will be only 18.2M OS and potentially 4-5 million float. Supply and demand should take care of it and push the price higher.

Worse if the market doesn’t give them the pps they want, they can intervene using another investment bank or themselves. Happens all the time. Whenever a company is taken public, it is the underwriters, responsibility to make sure that the pps stays above the offering price or certain % above it. With a float of 4-5 million they can manipulate the pps at their will and take it to a level, they are comfortable with.

I have a feeling they will go for a full-scale PR blitz immediately after the RS to make sure there is enough liquidity with upward price movement. No rocket science.

So if you go with a $500M valuation after the RS, divide that by 18.2 and you have a pps of around $27.5 that translate to $0.275 before split.

You think that is too high- make it half and you have a pps of $0.1375. Do whatever makes you comfortable. But these prices are not going to last.

Why is it trading below penny?

Because it is in OTC land and there are no investors here. You have small time traders with 3 days as their long term investment range. Plus the MM’s in OTC are not always designated and hence the stocks are on their own. No one to defend the price. That’s why you see sometime, 50% spread between bid and ask or a fall of 50%. These are all OTC specific.

After the RS and up-listing, there will be designated MM’s to defend the pps, and you will not see these level of fluctuations or spread. Plus you will have a new set of investors as most of the OTC traders will eventually leave and come back to other penny’s ? to lose money.

JMHO. No agenda here.

Good Luck.



Solaris Power Cells, Inc (SPCL) Stock Research Links

SPCL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aurora Innovation Faces Legal Heat Amid Delays

Updated Category News Views 76

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 92

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 88

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
Mynd.ai Alters ADS Ratio Affecting Share Dynamics

Updated Category News Views 82

Analyzing Mynd.ai's ADS Ratio Tweak When Mynd.ai decides to shake things up with the American Depositary Shares (ADS) ratio, it's like they're throwing a curveball straight at Wall Street. Listen up, this isn't just a deck shuffle—it's a fundamental tweak that could play a big role in the stock’s perceived value. Starting December 7, 2027, one ADS will leap from...

Continue Reading
James Hardie Joins S&P MidCap 400; Roku Acquired

Updated Category News Views 80

A Shift in the MidCap 400: What's Up? Well, wouldn’t you know it, James Hardie Industries is making waves as it steps into the S&P MidCap 400. This move happens because Fox Corp. has nabbed Roku in a deal worthy of some popcorn. Come November 11, when the trading floor wakes up, James Hardie will be in and Roku will be out. Pretty neat switcheroo if you ask me. Inside...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 100

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Madrigal Faces Legal Scrutiny Amid Whistleblower Claims

Updated Category News Views 204

The Storm Brewing Over Madrigal Pharmaceuticals Well, folks, here we are smack dab in the middle of another roller-coaster ride in the biotech sector, and it ain't pretty. Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is in hot water with some serious allegations thrown their way. The company is now under investigation by Kessler Topaz Meltzer & Check, LLP, a top-notch...

Continue Reading
Nemazee Fellowship Advances Clemency and Justice Reform

Updated Category News Views 96

Nemazee Fellowship: A Catalyst for Change You're probably wondering what's really happening when a couple like Hassan and Nazie Nemazee put their name on a legal fellowship. Skipping the melodrama, it's all about making a dent in the criminal justice system. These two aren't just slapping their name on a plaque—they're throwing real support behind actions that matter....

Continue Reading
Havertys Dividend: A Steady Payout Tradition Continues

Updated Category News Views 163

Another Year, Another Dividend for Havertys Man, talk about a company with a rock-solid habit. Havertys Furniture Companies (NYSE: HVT) just announced its latest cash dividend, cementing a tradition that's been rolling since 1935. They're dropping $0.33 per share on the common stock and $0.31 on the Class A common stock. It's set to hit investors' pockets by December 9,...

Continue Reading
IRTC Faces Investigation: Shares Plunge Amid Uncertainty

Updated Category News Views 63

Securities Trouble on the Horizon: IRTC Takes a Hit Wake up and adjust your seat, folks—iRhythm Technologies (NASDAQ:IRTC) is in the spotlight, and it ain't pretty. Shares nosedived over 30% in a single morning, stirring up quite the murky waters for shareholders. The trigger? A less-than-stellar third-quarter report. The Numbers Don't Lie—Or Do They? Management...

Continue Reading

Top 5 Most Recently Viewed Articles

Apertura Gene Therapy Collaborates on Prion Disease Treatment

Updated Category News Views 123

Apertura Gene Therapy Teams Up with Broad Institute Apertura Gene Therapy, a leading biotechnology firm committed to pioneering solutions in gene therapy, is collaborating with the Broad Institute, which is renowned for its groundbreaking research initiatives. The project aims to advance the development of a novel gene therapy targeting prion disease using an engineered...

Continue Reading
Bausch & Lomb Exceeds Expectations with Strong Q3 Growth

Updated Category News Views 67

Bausch & Lomb Achieves Impressive Third Quarter Results Bausch & Lomb Corp. (NYSE:BLCO) has recently captured attention in the financial markets after delivering strong third-quarter results for 2024. H.C. Wainwright, a prominent investment firm, revised the stock price target upward to $23.00 from the previous $22.00 while maintaining a Buy rating on the stock. This...

Continue Reading
Experience Winter Delights with BIGGBY® COFFEE's TWIX® Treats

Updated Category News Views 141

Discover the Seasonal Magic of BIGGBY® COFFEE The new limited-time winter offerings from BIGGBY® COFFEE are designed to delight cocoa and coffee lovers alike. This season, fans can indulge in a unique Salted Caramel lineup inspired by TWIX® candy. These festive beverages are available from early January through late February, providing a decadent way to enjoy the...

Continue Reading
Borr Drilling Limited's New Offering: What Investors Should Know

Updated Category News Views 229

Borr Drilling Limited Plans Significant Share Offering Borr Drilling Limited (NYSE: BORR) has recently announced plans to conduct a public offering of its common shares, intending to raise approximately $85 million in gross proceeds. The company aims to offer around 21 million shares in this equity initiative, reflecting its commitment to continued growth and investment...

Continue Reading